These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 31359514)
1. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes. Moradi-Marjaneh R; Paseban M; Sahebkar A Phytother Res; 2019 Oct; 33(10):2518-2530. PubMed ID: 31359514 [TBL] [Abstract][Full Text] [Related]
2. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice. Dutta D; Kalra S J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168 [TBL] [Abstract][Full Text] [Related]
3. Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits. Jackson K; Moseley KF Curr Osteoporos Rep; 2020 Oct; 18(5):439-448. PubMed ID: 32710428 [TBL] [Abstract][Full Text] [Related]
4. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105 [TBL] [Abstract][Full Text] [Related]
6. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus. Said S; Hernandez GT Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022 [TBL] [Abstract][Full Text] [Related]
7. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. Madaan T; Akhtar M; Najmi AK Eur J Pharm Sci; 2016 Oct; 93():244-52. PubMed ID: 27531551 [TBL] [Abstract][Full Text] [Related]
8. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics. Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977 [TBL] [Abstract][Full Text] [Related]
11. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Kurosaki E; Ogasawara H Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279 [TBL] [Abstract][Full Text] [Related]
12. Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. Inoue D; Nishi H; Inoue R; Nangaku M Int Heart J; 2021; 62(3):592-600. PubMed ID: 34054000 [TBL] [Abstract][Full Text] [Related]
13. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life. Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170 [TBL] [Abstract][Full Text] [Related]
14. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Lupsa BC; Inzucchi SE Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031 [TBL] [Abstract][Full Text] [Related]
16. The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment. Andrianesis V; Doupis J Expert Rev Clin Pharmacol; 2013 Sep; 6(5):519-39. PubMed ID: 23978089 [TBL] [Abstract][Full Text] [Related]
17. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. Kurozumi A; Okada Y; Tanaka Y Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570 [TBL] [Abstract][Full Text] [Related]
19. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions. Matharu K; Chana K; Ferro CJ; Jones AM Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753 [TBL] [Abstract][Full Text] [Related]
20. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin. Brady JA; Hallow KM J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]